
UPDATE ON LIRAGLUTIDE (SAXENDA[®]) FOR WEIGHT MANAGEMENT



The HSE introduced a managed access protocol (MAP) for liraglutide (Saxenda[®]) in January 2023. The aim of the MAP is to provide patients with an initial body mass index (BMI) greater than or equal to 35 kg/m², with prediabetes and high-risk for cardiovascular disease, with access to liraglutide (Saxenda[®]) for weight management.

Liraglutide (Saxenda[®]) is a glucagon-like peptide-1 analogue, and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients.

By October 2023, over 1,400 patients were accessing treatment with liraglutide (Saxenda[®]) under the Community Drug Schemes. Between January and September 2023, expenditure on liraglutide (Saxenda®) under the Drugs Payment and General Medical Services schemes was €1.8 million.

December 2023

HSE Medicines Management Programme.